CTX-130 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in T-Cell Lymphomas. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CTX-130’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for CTX-130 is expected to reach an annual total of $36 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CTX-130 Overview

CTX-130 is under development for the treatment of relapsed or refractory T cell lymphoma, diffuse large B-cell lymphoma, metastatic renal cell carcinoma, mycosis fungoides and sezary syndrome (MF/SS). The therapeutic candidate comprises of allogeneic T cells engineered to express chimeric antigen receptors (CAR T-cells) targeting cancer cells expressing CD70. It is administered through intravenous route and is being developed based on CRISPR’s gene-editing technology. 

CRISPR Therapeutics Overview

CRISPR Therapeutics is a gene editing company. The company’s portfolio consists of multiple therapeutic programs, including its proprietary technology, CRISPR (Clustered, Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR-associated protein-9), to precisely alter specific sequences of genomic deoxyribonucleic acid (DNA). The company’s products are primarily used in the healthcare industry, specifically in the treatment and prevention of both rare and common diseases. Its portfolio includes multiple therapeutic programs in areas such as hemoglobinopathies, immuno-oncology, autoimmune diseases, and type 1 diabetes. The company’s advanced program, Casgevy, is approved for treating severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CRISPR Therapeutics is headquartered in Zug, Switzerland.
The company reported revenues of (US Dollars) US$371.2 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$1.2 million in FY2022. The operating loss of the company was US$222.5 million in FY2023, compared to an operating loss of US$673.2 million in FY2022. The net loss of the company was US$153.6 million in FY2023, compared to a net loss of US$650.2 million in FY2022. The company reported revenues of US$0.5 million for the second quarter ended June 2024, an increase of 2.6% over the previous quarter.

For a complete picture of CTX-130’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 11 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.